Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31189274 | 1.00 | PTPN11 (0.42) | PTPN11 | |
| SCHEMBL21845354 | 0.87 | PTPN11 (0.40) | PTPN11 | |
| SCHEMBL23562136 | 0.85 | PTPN11 (0.44) | PTPN11 | |
| SCHEMBL21807493 | 0.84 | PTPN11 (0.46) | PTPN11 | |
| SCHEMBL21807522 | 0.84 | PTPN11 (0.46) | PTPN11 | |
| SCHEMBL31189266 | 0.84 | PTPN11 (0.46) | PTPN11 | |
| SCHEMBL21887740 | 0.83 | PTPN11 (0.39) | PTPN11 | |
| SCHEMBL21807025 | 0.83 | PTPN11 (0.39) | PTPN11 | |
| SCHEMBL21807106 | 0.83 | PTPN11 (0.39) | PTPN11 | |
| SCHEMBL21807010 | 0.83 | PTPN11 (0.39) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | claimed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | claimed |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-06-24 | — | — | US | claimed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3853234-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | Nikang Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| WO-2020061103-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 27/4885 |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | SRC, PTPRCAP, PTPRC | PTPN11 27/4885 |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 27/4885 |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.